{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:48:30Z","timestamp":1784234910458,"version":"3.55.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02099-2","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:34:57Z","timestamp":1772696097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances"],"prefix":"10.1007","volume":"26","author":[{"given":"Saeed Khavari","family":"Khorasani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavash","family":"Boroumandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Darzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahla","family":"Shokouhfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Abdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Eini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Ghorbani","family":"Vanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Bahrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"8","key":"2099_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081582","volume":"16","author":"S Zheng","year":"2024","unstructured":"Zheng S, et al. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges. Cancers. 2024;16(8).","journal-title":"Cancers"},{"issue":"6","key":"2099_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"issue":"1","key":"2099_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","volume":"24","author":"DY Kim","year":"2024","unstructured":"Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer. 2024;24(1):62\u201370.","journal-title":"J Liver Cancer"},{"key":"2099_CR4","doi-asserted-by":"publisher","unstructured":"Tarao K et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment, Cancer Med., vol. 8, no. 3, pp. 1054\u20131065, 2019, https:\/\/doi.org\/10.1002\/CAM4.1998","DOI":"10.1002\/CAM4.1998"},{"issue":"6","key":"2099_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.21037\/hbsn-23-539","volume":"12","author":"F Gao","year":"2023","unstructured":"Gao F, Chen G, Byrne CD, Targher G, Cheung TT, Zheng M-H. Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future. Hepatobiliary Surg Nutr. 2023;12(6):945.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2099_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1213145","volume":"14","author":"S Shoraka","year":"2023","unstructured":"Shoraka S, Hosseinian SM, Hasibi A, Ghaemi A, Mohebbi SR. The role of hepatitis B virus genome variations in HBV-related HCC: effects on host signaling pathways. Front Microbiol. 2023;14.","journal-title":"Front Microbiol"},{"key":"2099_CR7","doi-asserted-by":"publisher","unstructured":"Ayuso C, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. Apr. 2018;101:72\u201381. https:\/\/doi.org\/10.1016\/J.EJRAD.2018.01.025.","DOI":"10.1016\/J.EJRAD.2018.01.025"},{"key":"2099_CR8","doi-asserted-by":"publisher","unstructured":"Mueller C, et al. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut. May 2018;67(5):991\u20133. https:\/\/doi.org\/10.1136\/GUTJNL-2017-314981.","DOI":"10.1136\/GUTJNL-2017-314981"},{"key":"2099_CR9","doi-asserted-by":"crossref","unstructured":"Attia AM et al. Novel biomarkers for early detection of hepatocellular carcinoma, Diagnostics, vol. 14, no. 20, p. 2278, 2024.","DOI":"10.3390\/diagnostics14202278"},{"key":"2099_CR10","doi-asserted-by":"publisher","unstructured":"Sanyal J, Castera L, Wong VWS. Noninvasive Assessment of Liver Fibrosis in NAFLD, Clinical Gastroenterology and Hepatology, vol. 21, no. 8, pp. 2026\u20132039, Jul. 2023, https:\/\/doi.org\/10.1016\/j.cgh.2023.03.042","DOI":"10.1016\/j.cgh.2023.03.042"},{"key":"2099_CR11","doi-asserted-by":"publisher","unstructured":"Marin JJG et al. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma, Cancers (Basel)., vol. 12, no. 6, pp. 1\u201326, 2020, https:\/\/doi.org\/10.3390\/CANCERS12061663","DOI":"10.3390\/CANCERS12061663"},{"key":"2099_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1430991","volume":"14","author":"J Zhonghao","year":"2024","unstructured":"Zhonghao J, Fan Y. New advances in the treatment of intermediate and advanced hepatocellular carcinoma. Front Oncol. 2024;14.","journal-title":"Front Oncol"},{"key":"2099_CR13","doi-asserted-by":"publisher","unstructured":"Koza A, Bhogal RH, Fotiadis N, Mavroeidis VK. The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes, Biomedicines, vol. 11, no. 4, Apr. 2023, https:\/\/doi.org\/10.3390\/BIOMEDICINES11041062","DOI":"10.3390\/BIOMEDICINES11041062"},{"key":"2099_CR14","doi-asserted-by":"publisher","unstructured":"Hua X, Yin Z, Liang J, Chen W, Gong H. Efficacy and safety comparison between lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. Eur J Gastroenterol Hepatol. Jan. 2024;36(1):120\u20138. https:\/\/doi.org\/10.1097\/MEG.0000000000002668.","DOI":"10.1097\/MEG.0000000000002668"},{"key":"2099_CR15","doi-asserted-by":"publisher","unstructured":"Kelley RK, et al. Comparative efficacy of Cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther. Jun. 2020;37(6):2678\u201395. https:\/\/doi.org\/10.1007\/S12325-020-01378-Y.","DOI":"10.1007\/S12325-020-01378-Y"},{"key":"2099_CR16","doi-asserted-by":"publisher","first-page":"1379622","DOI":"10.3389\/fimmu.2024.1379622","volume":"15","author":"Z Akbulut","year":"2024","unstructured":"Akbulut Z, Aru B, Ayd\u0131n F, Yan\u0131kkaya Demirel G. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Front Immunol. 2024;15:1379622.","journal-title":"Front Immunol"},{"issue":"5","key":"2099_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26051936","volume":"26","author":"M Bloom","year":"2025","unstructured":"Bloom M, Podder S, Dang H, Lin D. Advances in immunotherapy in hepatocellular carcinoma. Int J Mol Sci. 2025;26(5).","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2099_CR18","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/CM9.0000000000003060","volume":"137","author":"X Wang","year":"2024","unstructured":"Wang X, Lu J. Immunotherapy for hepatocellular carcinoma. Chin Med J. 2024;137(15):1765\u201376. https:\/\/doi.org\/10.1097\/CM9.0000000000003060.","journal-title":"Chin Med J"},{"issue":"4","key":"2099_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.14218\/JCTH.2023.00462","volume":"12","author":"H Wei","year":"2024","unstructured":"Wei H, Dong C, Li X. Treatment options for hepatocellular carcinoma using immunotherapy: present and future. J Clin Transl Hepatol. 2024;12(4):389. https:\/\/doi.org\/10.14218\/JCTH.2023.00462.","journal-title":"J Clin Transl Hepatol"},{"key":"2099_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/11795549221134832","volume":"16","author":"J-T Huang","year":"2022","unstructured":"Huang J-T, et al. Recent update on immunotherapy and its combination with interventional therapies for hepatocellular carcinoma. Clin Med Insights Oncol. 2022;16.","journal-title":"Clin Med Insights Oncol"},{"issue":"2","key":"2099_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05539-8","volume":"150","author":"R Zhang","year":"2024","unstructured":"Zhang R, et al. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review. J Cancer Res Clin Oncol. 2024;150(2).","journal-title":"J Cancer Res Clin Oncol"},{"key":"2099_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.21037\/tgh-23-11","volume":"8","author":"K Sankar","year":"2023","unstructured":"Sankar K, et al. Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers. Transl Gastroenterol Hepatol. 2023;8:29.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2099_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460282","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yang H, Li T, Zhang N. Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment. Front Immunol. 2024;15.","journal-title":"Front Immunol"},{"issue":"1","key":"2099_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01747-5","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Huang K, Yin Q, Wu X, Zhu M, Li M. Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy. Discov Oncol. 2025;16(1).","journal-title":"Discov Oncol"},{"issue":"1","key":"2099_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/S12943-025-02378-8","volume":"24","author":"X Su","year":"2025","unstructured":"Su X, Yan X, Zhang H. The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine. Mol Cancer. 2025;24(1). https:\/\/doi.org\/10.1186\/S12943-025-02378-8.","journal-title":"Mol Cancer"},{"issue":"11","key":"2099_CR26","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.jfma.2022.07.013","volume":"121","author":"S-C Huang","year":"2022","unstructured":"Huang S-C, Kao J-H. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. J Formos Med Assoc. 2022;121(11):2148\u201351.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"2099_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05613-w","volume":"22","author":"W Tong","year":"2024","unstructured":"Tong W, et al. Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment. J Transl Med. 2024;22(1).","journal-title":"J Transl Med"},{"issue":"13","key":"2099_CR28","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.7150\/ijbs.102706","volume":"20","author":"J Hong","year":"2024","unstructured":"Hong J, et al. Unveiling the role of mechanical microenvironment in hepatocellular carcinoma: molecular mechanisms and implications for therapeutic strategies. Int J Biol Sci. 2024;20(13):5239.","journal-title":"Int J Biol Sci"},{"key":"2099_CR29","doi-asserted-by":"publisher","unstructured":"Lu Y, Liu NM, Ali B, Zhang, Cui X. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol. Jan. 2023;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1039260\/PDF.","DOI":"10.3389\/FIMMU.2022.1039260\/PDF"},{"issue":"3","key":"2099_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.009.","journal-title":"Cancer Cell"},{"issue":"29","key":"2099_CR31","doi-asserted-by":"publisher","first-page":"19696","DOI":"10.1021\/JACS.4C07125","volume":"146","author":"M Ju","year":"2024","unstructured":"Ju M, Lee S, Marvich HM, Lin S. Accessing alkoxy radicals via frustrated radical pairs: diverse oxidative functionalizations of tertiary alcohols. J Am Chem Soc. 2024;146(29):19696\u2013703. https:\/\/doi.org\/10.1021\/JACS.4C07125.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"2099_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1).","journal-title":"Mol Cancer"},{"key":"2099_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111378","author":"KJ Lv","year":"2024","unstructured":"Lv KJ, et al. Cancer-associated fibroblasts promote the progression and chemoresistance of HCC by inducing IGF-1. Cell Signal. 2024. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111378.","journal-title":"Cell Signal"},{"key":"2099_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/S40001-025-02626-Z","author":"L Fu","year":"2025","unstructured":"Fu L, Gu X, Lou N, Li J, Xue C. Current research of the Notch pathway in hepatocellular carcinoma. Eur J Med Res. 2025. https:\/\/doi.org\/10.1186\/S40001-025-02626-Z.","journal-title":"Eur J Med Res"},{"key":"2099_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-023-11613-8","author":"J Zhao","year":"2023","unstructured":"Zhao J, et al. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12\/FOLR1. BMC Cancer. 2023. https:\/\/doi.org\/10.1186\/S12885-023-11613-8.","journal-title":"BMC Cancer"},{"key":"2099_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2023.1295257","author":"U Basak","year":"2023","unstructured":"Basak U, et al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/FIMMU.2023.1295257.","journal-title":"Front Immunol"},{"issue":"1","key":"2099_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44(1):1\u201328. https:\/\/doi.org\/10.1186\/S13046-025-03377-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"2099_CR38","doi-asserted-by":"publisher","DOI":"10.3892\/OR.2022.8282","author":"S Okikawa","year":"2022","unstructured":"Okikawa S, et al. Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer. Oncol Rep. 2022. https:\/\/doi.org\/10.3892\/OR.2022.8282.","journal-title":"Oncol Rep"},{"issue":"1","key":"2099_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS17010066","volume":"17","author":"M Singer","year":"2024","unstructured":"Singer M, et al. Modulation of tumor-associated macrophages to overcome immune suppression in the hepatocellular carcinoma microenvironment. Cancers. 2024;17(1). https:\/\/doi.org\/10.3390\/CANCERS17010066.","journal-title":"Cancers"},{"key":"2099_CR40","doi-asserted-by":"publisher","unstructured":"Zhang J, Liu Y, Mo K, Zhang B, Huang, Shang D. CD8\u2009+\u2009T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/FIMMU.2024.1476904\/PDF.","DOI":"10.3389\/FIMMU.2024.1476904\/PDF"},{"issue":"4","key":"2099_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","volume":"9","author":"MB Watowich","year":"2023","unstructured":"Watowich MB, Gilbert MR, Larion M. T cell exhaustion in malignant gliomas. Trends Cancer. 2023;9(4):270\u201392. https:\/\/doi.org\/10.1016\/j.trecan.2022.12.008.","journal-title":"Trends Cancer"},{"key":"2099_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2019.01146","author":"MT Masucci","year":"2019","unstructured":"Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/FONC.2019.01146.","journal-title":"Front Oncol"},{"key":"2099_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/S41420-024-01982-9","author":"R Zhai","year":"2024","unstructured":"Zhai R, et al. Neutrophil extracellular traps promote invasion and metastasis via NLRP3-mediated oral squamous cell carcinoma pyroptosis inhibition. Cell Death Discov. 2024. https:\/\/doi.org\/10.1038\/S41420-024-01982-9.","journal-title":"Cell Death Discov"},{"key":"2099_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/S10571-024-01488-Z","author":"A Di Vito","year":"2024","unstructured":"Di Vito A, et al. Extracellular matrix structure and interaction with immune cells in adult astrocytic tumors. Cell Mol Neurobiol. 2024. https:\/\/doi.org\/10.1007\/S10571-024-01488-Z.","journal-title":"Cell Mol Neurobiol"},{"key":"2099_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/JHC.S159693","volume":"6","author":"L-C Lu","year":"2019","unstructured":"Lu L-C, Chang C-J, Hsu C-H. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma. 2019;6:71. https:\/\/doi.org\/10.2147\/JHC.S159693.","journal-title":"J Hepatocell Carcinoma"},{"issue":"6","key":"2099_CR46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1158\/0008-5472.CAN-23-1796","volume":"84","author":"M Mu","year":"2024","unstructured":"Mu M, et al. Targeting ferroptosis-elicited inflammation suppresses hepatocellular carcinoma metastasis and enhances sorafenib efficacy. Cancer Res. 2024;84(6):841\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1796.","journal-title":"Cancer Res"},{"issue":"9","key":"2099_CR47","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/CAC2.12596","volume":"44","author":"J Chen","year":"2024","unstructured":"Chen J, Duan Y, Che J, Zhu J. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy. Cancer Commun. 2024;44(9):1047\u201370. https:\/\/doi.org\/10.1002\/CAC2.12596.","journal-title":"Cancer Commun"},{"key":"2099_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM14091161","author":"W Li","year":"2024","unstructured":"Li W, et al. Research progress on dendritic cells in hepatocellular carcinoma immune microenvironments. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/BIOM14091161.","journal-title":"Biomolecules"},{"issue":"5","key":"2099_CR49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/HEPR.13877","volume":"53","author":"L Yu","year":"2023","unstructured":"Yu L, et al. The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2023;53(5):417\u201331. https:\/\/doi.org\/10.1111\/HEPR.13877.","journal-title":"Hepatol Res"},{"issue":"3","key":"2099_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21147\/J.ISSN.1000-9604.2023.03.07","volume":"35","author":"J Zhang","year":"2023","unstructured":"Zhang J, Guo F, Li L, Zhang S, Wang Y. Immune evasion and therapeutic opportunities based on natural killer cells. Chin J Cancer Res. 2023;35(3):283\u201398. https:\/\/doi.org\/10.21147\/J.ISSN.1000-9604.2023.03.07.","journal-title":"Chin J Cancer Res"},{"key":"2099_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/S41572-020-00240-3","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021. https:\/\/doi.org\/10.1038\/S41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"2099_CR52","doi-asserted-by":"publisher","unstructured":"Lurje, et al. Treatment strategies for hepatocellular Carcinoma \u2013 a multidisciplinary approach. Int J Mol Sci. Mar. 2019;20(6). https:\/\/doi.org\/10.3390\/IJMS20061465.","DOI":"10.3390\/IJMS20061465"},{"key":"2099_CR53","doi-asserted-by":"publisher","unstructured":"T\u00fcmen, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines. Dec. 2022;10(12). https:\/\/doi.org\/10.3390\/BIOMEDICINES10123202.","DOI":"10.3390\/BIOMEDICINES10123202"},{"issue":"6","key":"2099_CR54","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3748\/WJG.V29.I6.1054","volume":"29","author":"S Mandlik","year":"2023","unstructured":"Mandlik S, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol. 2023;29(6):1054. https:\/\/doi.org\/10.3748\/WJG.V29.I6.1054.","journal-title":"World J Gastroenterol"},{"key":"2099_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-021-01164-5","author":"S Zhu","year":"2021","unstructured":"Zhu S, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/S13045-021-01164-5.","journal-title":"J Hematol Oncol"},{"key":"2099_CR56","doi-asserted-by":"publisher","unstructured":"Chulpanova DS, Kitaeva KV, Green AR, Rizvanov AA, Solovyeva VV. Molecular aspects and future perspectives of Cytokine-Based Anti-cancer immunotherapy. Front Cell Dev Biol. Jun. 2020;8. https:\/\/doi.org\/10.3389\/FCELL.2020.00402\/PDF.","DOI":"10.3389\/FCELL.2020.00402\/PDF"},{"key":"2099_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES11081357","author":"A Tojjari","year":"2023","unstructured":"Tojjari A, Saeed A, Singh M, Cavalcante L, Sahin IH, Saeed A. A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma. Vaccines. 2023. https:\/\/doi.org\/10.3390\/VACCINES11081357.","journal-title":"Vaccines"},{"issue":"12","key":"2099_CR58","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-21-4424","volume":"28","author":"MW L\u00f6ffler","year":"2022","unstructured":"L\u00f6ffler MW, et al. Phase I\/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. Clin Cancer Res. 2022;28(12):2555\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4424.","journal-title":"Clin Cancer Res"},{"key":"2099_CR59","doi-asserted-by":"publisher","unstructured":"Liu Y, Yang H, Li T, Zhang N. Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/FIMMU.2024.1460282\/PDF.","DOI":"10.3389\/FIMMU.2024.1460282\/PDF"},{"key":"2099_CR60","doi-asserted-by":"publisher","unstructured":"Zhang Q et al. Jun., Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)., Journal of Clinical Oncology, vol. 42, no. 16_suppl, pp. 4019\u20134019, 2024, https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.4019","DOI":"10.1200\/JCO.2024.42.16_SUPPL.4019"},{"issue":"6","key":"2099_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061808","volume":"15","author":"M Ozer","year":"2023","unstructured":"Ozer M, Goksu SY, Akagunduz B, George A, Sahin I. Adoptive cell therapy in hepatocellular carcinoma: a review of clinical trials. Cancers (Basel). 2023;15(6). https:\/\/doi.org\/10.3390\/cancers15061808.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2099_CR62","doi-asserted-by":"publisher","first-page":"103046","DOI":"10.1016\/j.ctrv.2025.103046","volume":"141","author":"R Elahi","year":"2025","unstructured":"Elahi R, Alami Idrissi Y, Saeed A. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treat Rev. 2025;141(2):103046. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103046.","journal-title":"Cancer Treat Rev"},{"key":"2099_CR63","doi-asserted-by":"publisher","unstructured":"Escobar TR, Berger, Maus MV. CAR-T cells in solid tumors: challenges and breakthroughs. Cell Rep Med. Nov. 2025;6(11):102353. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102353.","DOI":"10.1016\/j.xcrm.2025.102353"},{"issue":"8062","key":"2099_CR64","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/S41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen Y, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature. 2025;641(8062):503\u201311. https:\/\/doi.org\/10.1038\/S41586-025-08717-5.","journal-title":"Nature"},{"issue":"1","key":"2099_CR65","doi-asserted-by":"publisher","first-page":"100771","DOI":"10.1016\/j.ajps.2022.100771","volume":"18","author":"X Li","year":"2022","unstructured":"Li X, Sun X, Wang B, Li Y, Tong J. Oncolytic virus-based hepatocellular carcinoma treatment: current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J Pharm Sci. 2022;18(1):100771. https:\/\/doi.org\/10.1016\/j.ajps.2022.100771.","journal-title":"Asian J Pharm Sci"},{"issue":"7","key":"2099_CR66","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.32604\/or.2025.061857","volume":"33","author":"Y Ye","year":"2025","unstructured":"Ye Y, Liu Y. Oncolytic virus therapy in hepatocellular carcinoma. Oncol Res. 2025;33(7):1593. https:\/\/doi.org\/10.32604\/or.2025.061857.","journal-title":"Oncol Res"},{"key":"2099_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1380313","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhu M, Chi H, Liu Y, Yu G. The combination therapy of oncolytic virotherapy. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1380313.","journal-title":"Front Pharmacol"},{"issue":"16_suppl","key":"2099_CR68","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1200\/JCO.2024.42.16_SUPPL.2622","volume":"42","author":"SS Lee","year":"2024","unstructured":"Lee SS, et al. PERIO-02: phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +\/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. J Clin Oncol. 2024;42(16_suppl):2622\u20132622. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.2622.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2099_CR69","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMOA1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMOA1915745.","journal-title":"N Engl J Med"},{"issue":"3","key":"2099_CR70","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/S41571-021-00573-2","volume":"19","author":"M Llovet","year":"2022","unstructured":"Llovet M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151\u201372. https:\/\/doi.org\/10.1038\/S41571-021-00573-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10360","key":"2099_CR71","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-.","journal-title":"Lancet"},{"key":"2099_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1070961.","journal-title":"Front Immunol"},{"key":"2099_CR73","doi-asserted-by":"publisher","unstructured":"Sharafi, et al. A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. Cancer Cell Int. Dec. 2022;22(1). https:\/\/doi.org\/10.1186\/S12935-022-02682-Z.","DOI":"10.1186\/S12935-022-02682-Z"},{"key":"2099_CR74","doi-asserted-by":"publisher","unstructured":"Duffy AG, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. Mar. 2017;66(3):545\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2016.10.029.","DOI":"10.1016\/j.jhep.2016.10.029"},{"key":"2099_CR75","doi-asserted-by":"publisher","unstructured":"Finn RS et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma, J. Clin. Oncol., vol. 38, no. 26, pp. 2960\u20132970, 2020, https:\/\/doi.org\/10.1200\/JCO.20.00808","DOI":"10.1200\/JCO.20.00808"},{"key":"2099_CR76","doi-asserted-by":"publisher","unstructured":"Melero et al. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040, Annals of Oncology, vol. 35, no. 6, pp. 537\u2013548, 2024, https:\/\/doi.org\/10.1016\/j.annonc.2024.03.005","DOI":"10.1016\/j.annonc.2024.03.005"},{"key":"2099_CR77","doi-asserted-by":"publisher","unstructured":"Kudo M, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. Mar. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"2099_CR78","doi-asserted-by":"publisher","unstructured":"Abou-Alfa GK et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, N. Engl. J. Med., vol. 379, no. 1, pp. 54\u201363, 2018, https:\/\/doi.org\/10.1056\/NEJMOA1717002","DOI":"10.1056\/NEJMOA1717002"},{"key":"2099_CR79","doi-asserted-by":"publisher","unstructured":"R. Q et al., Clinical benefits of PD-1\/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int, 14, 5, 2020, https:\/\/doi.org\/10.1007\/S12072-020-10064-8","DOI":"10.1007\/S12072-020-10064-8"},{"key":"2099_CR80","doi-asserted-by":"publisher","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. Dec. 2022;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1070961\/PDF.","DOI":"10.3389\/FIMMU.2022.1070961\/PDF"},{"key":"2099_CR81","doi-asserted-by":"publisher","unstructured":"Kudo M et al. CheckMate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis, J. Hepatol., vol. 75, no. 3, pp. 600\u2013609, 2021, https:\/\/doi.org\/10.1016\/j.jhep.2021.04.047","DOI":"10.1016\/j.jhep.2021.04.047"},{"key":"2099_CR82","doi-asserted-by":"publisher","unstructured":"Yau T, et al. Nivolumab versus Sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. Jan. 2022;23(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5.","DOI":"10.1016\/S1470-2045(21)00604-5"},{"issue":"7","key":"2099_CR83","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2099_CR84","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193\u2013202. https:\/\/doi.org\/10.1200\/JCO.19.01307.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2099_CR85","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/JAMAONCOL.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(12):1651\u20139. https:\/\/doi.org\/10.1001\/JAMAONCOL.2023.4003.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2099_CR86","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(20)30011-5.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2099_CR87","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(20)30156-X.","journal-title":"Lancet Oncol"},{"key":"2099_CR88","doi-asserted-by":"publisher","unstructured":"Zhang, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. Dec. 2021;40(1). https:\/\/doi.org\/10.1186\/S13046-021-01987-7.","DOI":"10.1186\/S13046-021-01987-7"},{"key":"2099_CR89","doi-asserted-by":"publisher","unstructured":"Hossen MM, et al. Current Understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1198365\/PDF.","DOI":"10.3389\/FIMMU.2023.1198365\/PDF"},{"issue":"1","key":"2099_CR90","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2013.02.022.","journal-title":"J Hepatol"},{"key":"2099_CR91","doi-asserted-by":"publisher","unstructured":"Wu M, Yi S, Qin Q, Chu X, Zheng, Wu K. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: A meta-analysis. Exp Hematol Oncol. Oct. 2019;8(1):1\u201312. https:\/\/doi.org\/10.1186\/S40164-019-0150-0\/TABLES\/2.","DOI":"10.1186\/S40164-019-0150-0\/TABLES\/2"},{"issue":"4_suppl","key":"2099_CR92","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.2025.43.4_SUPPL.609","volume":"43","author":"AK Kim","year":"2025","unstructured":"Kim AK, et al. Safety and efficacy of combining PD-L1 and CTLA-4 blockade with transarterial chemoembolization in intermediate-stage hepatocellular carcinoma: a phase II study. J Clin Oncol. 2025;43(4_suppl):609\u2013609. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_SUPPL.609.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2099_CR93","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/OT9.0000000000000064","volume":"10","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Exploring combination therapy centered on targeted immunotherapy for advanced hepatocellular carcinoma: a beacon of hope. Oncol Transl Med. 2024;10(6):292\u20139. https:\/\/doi.org\/10.1097\/OT9.0000000000000064.","journal-title":"Oncol Transl Med"},{"issue":"2","key":"2099_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/J.ILIVER.2024.100092","volume":"3","author":"Z Li","year":"2024","unstructured":"Li Z, Zhong J, Zhang C, Zhang B, Shi X, Li L. Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: a real-world clinical study. iLIVER. 2024;3(2). https:\/\/doi.org\/10.1016\/J.ILIVER.2024.100092.","journal-title":"iLIVER"},{"key":"2099_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-022-10174-6","author":"TK Yang","year":"2022","unstructured":"Yang TK, et al. Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer. 2022. https:\/\/doi.org\/10.1186\/S12885-022-10174-6.","journal-title":"BMC Cancer"},{"issue":"2","key":"2099_CR96","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.003.","journal-title":"J Hepatol"},{"issue":"3","key":"2099_CR97","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/NRI.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195\u2013203. https:\/\/doi.org\/10.1038\/NRI.2017.145.","journal-title":"Nat Rev Immunol"},{"key":"2099_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1487610\/FULL","volume":"15","author":"Q Xu","year":"2024","unstructured":"Xu Q, Shao D. Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/FIMMU.2024.1487610\/FULL.","journal-title":"Front Immunol"},{"key":"2099_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13081949","author":"Y Dong","year":"2021","unstructured":"Dong Y, et al. Recent advances and future prospects in immune checkpoint (ICI)-based combination therapy for advanced HCC. Cancers. 2021. https:\/\/doi.org\/10.3390\/CANCERS13081949.","journal-title":"Cancers"},{"key":"2099_CR100","doi-asserted-by":"publisher","unstructured":"Zhu H, Zhao W, Chen H, Zhu X, You J, Jin C. Evaluation of the effectiveness and safety of combining PD-1\/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/FIMMU.2024.1468440\/PDF.","DOI":"10.3389\/FIMMU.2024.1468440\/PDF"},{"key":"2099_CR101","doi-asserted-by":"publisher","unstructured":"Zhu XD et al. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations, Liver Cancer, vol. 10, no. 4, pp. 320\u2013329, 2021, https:\/\/doi.org\/10.1159\/000514313","DOI":"10.1159\/000514313"},{"key":"2099_CR102","doi-asserted-by":"publisher","unstructured":"Liang LW, Luo RH, Huang ZL, Tang LN. Clinical observation of nivolumab combined with Cabozantinib in the treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol. Apr. 2025;17(4). https:\/\/doi.org\/10.4251\/WJGO.V17.I4.103631.","DOI":"10.4251\/WJGO.V17.I4.103631"},{"key":"2099_CR103","doi-asserted-by":"publisher","unstructured":"Qin S et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study, The Lancet, vol. 402, no. 10408, pp. 1133\u20131146, 2023, https:\/\/doi.org\/10.1016\/S0140-6736(23)00961-3","DOI":"10.1016\/S0140-6736(23)00961-3"},{"key":"2099_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-023-10960-W","author":"D Huang","year":"2023","unstructured":"Huang D, Ke L, Cui H, Li S. Efficacy and safety of PD-1\/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2023. https:\/\/doi.org\/10.1186\/S12885-023-10960-W.","journal-title":"BMC Cancer"},{"key":"2099_CR105","doi-asserted-by":"publisher","unstructured":"Yau T, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. 2020;6(11). https:\/\/doi.org\/10.1001\/JAMAONCOL.2020.4564.","DOI":"10.1001\/JAMAONCOL.2020.4564"},{"key":"2099_CR106","doi-asserted-by":"publisher","unstructured":"Abou-Alfa GK et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, NEJM evidence, vol. 1, no. 8, 2022, https:\/\/doi.org\/10.1056\/EVIDOA2100070","DOI":"10.1056\/EVIDOA2100070"},{"key":"2099_CR107","doi-asserted-by":"publisher","unstructured":"Rimassa L, et al. Five-year overall survival update from the HIMALAYA study of Tremelimumab plus durvalumab in unresectable HCC. J Hepatol. Oct. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.033.","DOI":"10.1016\/j.jhep.2025.03.033"},{"key":"2099_CR108","doi-asserted-by":"publisher","unstructured":"Yau T, et al. Nivolumab plus ipilimumab versus lenvatinib or Sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. May 2025;405(10492):1851\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"2099_CR109","doi-asserted-by":"publisher","unstructured":"Yuan G, et al. Cadonilimab (PD-1\/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study. Heliyon. Oct. 2024;10(19). https:\/\/doi.org\/10.1016\/J.HELIYON.2024.E37616.","DOI":"10.1016\/J.HELIYON.2024.E37616"},{"issue":"5","key":"2099_CR110","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro B, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.005.","journal-title":"Ann Oncol"},{"key":"2099_CR111","doi-asserted-by":"publisher","DOI":"10.1007\/S00262-025-04085-1","author":"S Li","year":"2025","unstructured":"Li S, et al. Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. Cancer Immunol Immunother. 2025. https:\/\/doi.org\/10.1007\/S00262-025-04085-1.","journal-title":"Cancer Immunol Immunother"},{"key":"2099_CR112","doi-asserted-by":"publisher","unstructured":"Shen, et al. Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with Sorafenib for advanced hepatocellular carcinoma in Barcelona clinic liver cancer stage C (Double-IA-001): a phase II trial. BMC Med. Dec. 2025;23(1). https:\/\/doi.org\/10.1186\/S12916-025-04110-1.","DOI":"10.1186\/S12916-025-04110-1"},{"issue":"5","key":"2099_CR113","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21037\/CCO-23-159","volume":"13","author":"SY Son","year":"2024","unstructured":"Son SY, Yarmohammadi H. Combining immunotherapy\/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma. Chin Clin Oncol. 2024;13(5):79. https:\/\/doi.org\/10.21037\/CCO-23-159.","journal-title":"Chin Clin Oncol"},{"key":"2099_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1471017","author":"YC Lu","year":"2024","unstructured":"Lu YC, et al. FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/FIMMU.2024.1471017.","journal-title":"Front Immunol"},{"key":"2099_CR115","doi-asserted-by":"publisher","unstructured":"Kudo, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. Jan. 2025;405(10474):203\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3.","DOI":"10.1016\/S0140-6736(24)02575-3"},{"key":"2099_CR116","doi-asserted-by":"publisher","unstructured":"Li, et al. Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria. J Immunother Cancer. Jan. 2025;13(1). https:\/\/doi.org\/10.1136\/JITC-2024-010035.","DOI":"10.1136\/JITC-2024-010035"},{"issue":"10474","key":"2099_CR117","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474):216\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)02551-0.","journal-title":"Lancet"},{"key":"2099_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-024-53704-5","author":"H Pan","year":"2024","unstructured":"Pan H, et al. Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/S41467-024-53704-5.","journal-title":"Nat Commun"},{"key":"2099_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100991","author":"BH Kim","year":"2024","unstructured":"Kim BH, et al. Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: a phase II study. JHEP Rep. 2024. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100991.","journal-title":"JHEP Rep"},{"issue":"1","key":"2099_CR120","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/J.IJROBP.2022.09.052","volume":"115","author":"A Juloori","year":"2023","unstructured":"Juloori A, et al. Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2023;115(1):202\u201313. https:\/\/doi.org\/10.1016\/J.IJROBP.2022.09.052.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2099_CR121","doi-asserted-by":"publisher","unstructured":"De La Torre-Al\u00e1ez, et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer. Nov. 2022;10(11). https:\/\/doi.org\/10.1136\/JITC-2022-005457.","DOI":"10.1136\/JITC-2022-005457"},{"key":"2099_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.839605","author":"YJ Xiang","year":"2022","unstructured":"Xiang YJ, et al. Effects of stereotactic body radiation therapy plus PD-1 inhibitors for patients with transarterial chemoembolization refractory. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/FONC.2022.839605.","journal-title":"Front Oncol"},{"issue":"4","key":"2099_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/OL.2025.15206","volume":"30","author":"R Cui","year":"2025","unstructured":"Cui R, Yu X, Jiang Y, Li X. Efficacy and safety of the immune checkpoint inhibitor-radiotherapy combination in advanced\/unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Oncol Lett. 2025;30(4):1\u201321. https:\/\/doi.org\/10.3892\/OL.2025.15206.","journal-title":"Oncol Lett"},{"key":"2099_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/J.CANLET.2022.216038","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang Y, Gao P, Ding J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett. 2023. https:\/\/doi.org\/10.1016\/J.CANLET.2022.216038.","journal-title":"Cancer Lett"},{"key":"2099_CR125","doi-asserted-by":"publisher","unstructured":"Hernandez R, Malek TR. Fueling cancer vaccines to improve T Cell-Mediated antitumor immunity. Front Oncol. May 2022;12. https:\/\/doi.org\/10.3389\/FONC.2022.878377\/PDF.","DOI":"10.3389\/FONC.2022.878377\/PDF"},{"key":"2099_CR126","doi-asserted-by":"publisher","unstructured":"Hemminki JM, Dos Santos, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. Jun. 2020;13(1). https:\/\/doi.org\/10.1186\/S13045-020-00922-1.","DOI":"10.1186\/S13045-020-00922-1"},{"issue":"4","key":"2099_CR127","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/J.CELL.2018.07.035","volume":"174","author":"A Ribas","year":"2018","unstructured":"Ribas A, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2018;174(4):1031\u20132. https:\/\/doi.org\/10.1016\/J.CELL.2018.07.035.","journal-title":"Cell"},{"key":"2099_CR128","doi-asserted-by":"publisher","unstructured":"Vienot et al. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82), BMC Cancer, vol. 23, no. 1, 2023, https:\/\/doi.org\/10.1186\/S12885-023-11065-0","DOI":"10.1186\/S12885-023-11065-0"},{"issue":"4","key":"2099_CR129","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/S41591-024-02894-Y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med. 2024;30(4):1044\u201353. https:\/\/doi.org\/10.1038\/S41591-024-02894-Y.","journal-title":"Nat Med"},{"key":"2099_CR130","doi-asserted-by":"publisher","unstructured":"Yi, et al. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study. ESMO Open. Feb. 2024;9(2). https:\/\/doi.org\/10.1016\/J.ESMOOP.2024.102239.","DOI":"10.1016\/J.ESMOOP.2024.102239"},{"key":"2099_CR131","doi-asserted-by":"publisher","unstructured":"Miao Z, Zhang Z, Ren, Li Y. Application of immunotherapy in hepatocellular carcinoma. Front Oncol. Aug. 2021;11:699060. https:\/\/doi.org\/10.3389\/fonc.2021.699060.","DOI":"10.3389\/fonc.2021.699060"},{"issue":"3","key":"2099_CR132","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo J, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19(3):329\u201336. https:\/\/doi.org\/10.1038\/nm.3089.","journal-title":"Nat Med"},{"issue":"1","key":"2099_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. Journal of Hematology & Oncology 2024 17:1. 2024;17(1). https:\/\/doi.org\/10.1186\/s13045-024-01549-2.","journal-title":"Journal of Hematology & Oncology 2024 17:1"},{"issue":"10","key":"2099_CR134","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/oncolo\/oyae110","volume":"29","author":"D Cowzer","year":"2024","unstructured":"Cowzer D, et al. Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy. Oncologist. 2024;29(10):894\u2013903. https:\/\/doi.org\/10.1093\/oncolo\/oyae110.","journal-title":"Oncologist"},{"key":"2099_CR135","doi-asserted-by":"publisher","unstructured":"Xie P, Zhang Y, Wang W, Mei, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: challenges and opportunities. Front Oncol. Sep. 2022;12. https:\/\/doi.org\/10.3389\/FONC.2022.958720\/PDF.","DOI":"10.3389\/FONC.2022.958720\/PDF"},{"key":"2099_CR136","doi-asserted-by":"publisher","unstructured":"qing, Dong, et al. Heterogeneous Immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. May 2020;72(5):896\u2013908. https:\/\/doi.org\/10.1016\/J.JHEP.2019.12.014.","DOI":"10.1016\/J.JHEP.2019.12.014"},{"key":"2099_CR137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154515","author":"C Xu","year":"2022","unstructured":"Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. \u03b2-catenin signaling in hepatocellular carcinoma. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI154515.","journal-title":"J Clin Invest"},{"issue":"11","key":"2099_CR138","doi-asserted-by":"publisher","first-page":"9789","DOI":"10.3390\/CURRONCOL30110711","volume":"30","author":"F Bicer","year":"2023","unstructured":"Bicer F, Kure C, Ozluk AA, El-Rayes BF, Akce M. Advances in immunotherapy for hepatocellular carcinoma (HCC). Curr Oncol. 2023;30(11):9789\u2013812. https:\/\/doi.org\/10.3390\/CURRONCOL30110711.","journal-title":"Curr Oncol"},{"key":"2099_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24032652","author":"LY Tian","year":"2023","unstructured":"Tian LY, Smit DJ, J\u00fccker M. The role of PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/IJMS24032652.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2099_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/S40001-024-02073-2","volume":"29","author":"AR Devan","year":"2024","unstructured":"Devan AR, et al. The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential. Eur J Med Res. 2024;29(1). https:\/\/doi.org\/10.1186\/S40001-024-02073-2.","journal-title":"Eur J Med Res"},{"issue":"8","key":"2099_CR141","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/S41591-022-01868-2","volume":"28","author":"X Zhu","year":"2022","unstructured":"Zhu X, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599\u2013611. https:\/\/doi.org\/10.1038\/S41591-022-01868-2.","journal-title":"Nat Med"},{"key":"2099_CR142","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.2147\/JHC.S291553","volume":"10","author":"GF Manfredi","year":"2023","unstructured":"Manfredi GF, et al. Mechanisms of resistance to immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1955\u201371. https:\/\/doi.org\/10.2147\/JHC.S291553.","journal-title":"J Hepatocell Carcinoma"},{"key":"2099_CR143","doi-asserted-by":"publisher","unstructured":"Suthen S et al. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC, Hepatology, vol. 76, no. 5, pp. 1329\u20131344, 2022, https:\/\/doi.org\/10.1002\/HEP.32419","DOI":"10.1002\/HEP.32419"},{"key":"2099_CR144","doi-asserted-by":"publisher","unstructured":"De Cicco G, Ercolano, Ianaro A. The new era of cancer immunotherapy: targeting Myeloid-Derived suppressor cells to overcome immune evasion. Front Immunol. Jul. 2020;11. https:\/\/doi.org\/10.3389\/FIMMU.2020.01680.","DOI":"10.3389\/FIMMU.2020.01680"},{"key":"2099_CR145","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.2147\/JIR.S460931","volume":"17","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yin Y, Tang J, Zhang Y, Tian Y, Sun F. Changes in serum interleukin-8 levels predict response to immune checkpoint inhibitors immunotherapy in unresectable hepatocellular carcinoma patients. J Inflamm Res. 2024;17:3397\u2013406. https:\/\/doi.org\/10.2147\/JIR.S460931.","journal-title":"J Inflamm Res"},{"issue":"4","key":"2099_CR146","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.ymthe.2025.02.002","volume":"33","author":"TT Kwong","year":"2025","unstructured":"Kwong TT, et al. Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8\/CXCR2 signaling. Mol Ther. 2025;33(4):1659\u201373. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.002.","journal-title":"Mol Ther"},{"key":"2099_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2024.107161","volume":"203","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Tan H, Wang J, Zhuang H, Zhao H, Lu X. Molecular insight into T cell exhaustion in hepatocellular carcinoma. Pharmacol Res. 2024;203. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107161.","journal-title":"Pharmacol Res"},{"key":"2099_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2023.1150985","volume":"14","author":"CL Cheung","year":"2023","unstructured":"Cheung CL, et al. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1150985.","journal-title":"Front Immunol"},{"key":"2099_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/FIMMU.2021.699895.","journal-title":"Front Immunol"},{"issue":"2","key":"2099_CR150","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1053\/j.gastro.2020.03.074","volume":"159","author":"KC Chiu","year":"2020","unstructured":"Chiu KC, et al. Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterology. 2020;159(2):609\u201323. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.074.","journal-title":"Gastroenterology"},{"key":"2099_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2025.1620075","volume":"16","author":"X Shi","year":"2025","unstructured":"Shi X, Zhu W, Zhang J, Fan C, Zhang J. Cancer-associated fibroblasts in hepatocellular carcinoma: origins, heterogeneity, and therapeutic implications. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/FIMMU.2025.1620075.","journal-title":"Front Immunol"},{"key":"2099_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15082276","author":"J Colard-Thomas","year":"2023","unstructured":"Colard-Thomas J, Thomas QD, Viala M. Comedications with immune checkpoint inhibitors: involvement of the microbiota, impact on efficacy and practical implications. Cancers. 2023. https:\/\/doi.org\/10.3390\/CANCERS15082276.","journal-title":"Cancers"},{"issue":"12","key":"2099_CR153","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2021-003334","volume":"9","author":"J Mao","year":"2021","unstructured":"Mao J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2021;9(12). https:\/\/doi.org\/10.1136\/JITC-2021-003334.","journal-title":"J Immunother Cancer"},{"key":"2099_CR154","doi-asserted-by":"publisher","unstructured":"Xie P, Zhang Y, Wang W, Mei, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: challenges and opportunities. Front Oncol. Sep. 2022;12:958720. https:\/\/doi.org\/10.3389\/FONC.2022.958720\/BIBTEX.","DOI":"10.3389\/FONC.2022.958720\/BIBTEX"},{"issue":"1","key":"2099_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24(1):1\u201320. https:\/\/doi.org\/10.1186\/S12943-024-02212-7.","journal-title":"Mol Cancer"},{"key":"2099_CR156","doi-asserted-by":"publisher","unstructured":"Hsiehchen, et al. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nat Commun. Dec. 2024;15(1):1\u201310. https:\/\/doi.org\/10.1038\/S41467-024-46542-Y;SUBJMETA.","DOI":"10.1038\/S41467-024-46542-Y;SUBJMETA"},{"issue":"6","key":"2099_CR157","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/S41423-022-00848-3","volume":"19","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, et al. The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma. Cell Mol Immunol. 2022;19(6):726\u201337. https:\/\/doi.org\/10.1038\/S41423-022-00848-3.","journal-title":"Cell Mol Immunol"},{"key":"2099_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24043625","author":"N Shivapurkar","year":"2023","unstructured":"Shivapurkar N, et al. Treatment with a cholecystokinin receptor antagonist, proglumide, improves efficacy of immune checkpoint antibodies in hepatocellular carcinoma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/IJMS24043625.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2099_CR159","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/IMT-2022-0185","volume":"15","author":"J Abi-Aad","year":"2023","unstructured":"Abi-Aad J, Zouein J, Chartouni A, Naim N, Kourie HR. Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy? Immunotherapy. 2023;15(8):611\u20138. https:\/\/doi.org\/10.2217\/IMT-2022-0185.","journal-title":"Immunotherapy"},{"issue":"8","key":"2099_CR160","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CJI.0000000000000330","volume":"43","author":"C Zhang","year":"2020","unstructured":"Zhang C, et al. TIGIT can exert immunosuppressive effects on CD8\u2009+\u2009T cells by the CD155\/TIGIT signaling pathway for hepatocellular carcinoma in vitro. J Immunother. 2020;43(8):236. https:\/\/doi.org\/10.1097\/CJI.0000000000000330.","journal-title":"J Immunother"},{"issue":"8","key":"2099_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00262-025-04128-7\/FIGURES\/2","volume":"74","author":"C Sundstrom","year":"2025","unstructured":"Sundstrom C, Huang X, Wiemer AJ. Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms. Cancer Immunol Immunother. 2025;74(8):1\u201314. https:\/\/doi.org\/10.1007\/S00262-025-04128-7\/FIGURES\/2.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2099_CR162","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","volume":"25","author":"HJ Chon","year":"2019","unstructured":"Chon HJ, et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin Cancer Res. 2019;25(5):1612\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1932.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2099_CR163","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/1878-0261.13146","volume":"16","author":"JL Gulley","year":"2022","unstructured":"Gulley JL, et al. Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2022;16(11):2117\u201334. https:\/\/doi.org\/10.1002\/1878-0261.13146.","journal-title":"Mol Oncol"},{"key":"2099_CR164","doi-asserted-by":"publisher","unstructured":"Tao S, Liang T, Zeng, Yin D. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint Inhibition. Front Immunol. Jan. 2023;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1043667\/PDF.","DOI":"10.3389\/FIMMU.2022.1043667\/PDF"},{"key":"2099_CR165","doi-asserted-by":"publisher","unstructured":"Shen C, et al. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1170207\/PDF.","DOI":"10.3389\/FIMMU.2023.1170207\/PDF"},{"issue":"10","key":"2099_CR166","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/GUTJNL-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie J, et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022;71(10):2093\u2013106. https:\/\/doi.org\/10.1136\/GUTJNL-2021-326259.","journal-title":"Gut"},{"issue":"6","key":"2099_CR167","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"S Lee","year":"2020","unstructured":"Lee S, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(20)30156-X.","journal-title":"Lancet Oncol"},{"key":"2099_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43381-1","author":"S Cappuyns","year":"2023","unstructured":"Cappuyns S, et al. PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10\u2009+\u2009macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat Commun. 2023. https:\/\/doi.org\/10.1038\/s41467-023-43381-1.","journal-title":"Nat Commun"},{"issue":"6","key":"2099_CR169","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/J.JHEP.2024.12.016","volume":"82","author":"S Cappuyns","year":"2025","unstructured":"Cappuyns S, et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab\u2009+\u2009bevacizumab in advanced hepatocellular carcinoma. J Hepatol. 2025;82(6):1036\u201349. https:\/\/doi.org\/10.1016\/J.JHEP.2024.12.016.","journal-title":"J Hepatol"},{"issue":"11","key":"2099_CR170","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol. 2023;20(11):780\u201398. https:\/\/doi.org\/10.1038\/s41571-023-00816-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"2099_CR171","doi-asserted-by":"publisher","unstructured":"de Galarreta MR et al. Aug., \u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma, Cancer Discov., vol. 9, no. 8, p. 10.1158\/2159\u20138290.CD-19\u20130074, 2019, https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0074","DOI":"10.1158\/2159-8290.CD-19-0074"},{"issue":"7","key":"2099_CR172","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","volume":"25","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt\/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res. 2019;25(7):2021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3778.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2099_CR173","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion M, et al. Somatic hla class i loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 2021;11(2):282\u201392. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0672.","journal-title":"Cancer Discov"},{"issue":"11","key":"2099_CR174","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007479","volume":"11","author":"J Yu","year":"2023","unstructured":"Yu J, et al. TP53\/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma. J Immunother Cancer. 2023;11(11). https:\/\/doi.org\/10.1136\/jitc-2023-007479.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2099_CR175","doi-asserted-by":"publisher","first-page":"9","DOI":"10.17998\/JLC.2023.11.21","volume":"24","author":"YG Song","year":"2024","unstructured":"Song YG, Yoo JJ, Kim SG, Kim YS. Complications of immunotherapy in advanced hepatocellular carcinoma. J Liver Cancer. 2024;24(1):9\u201316. https:\/\/doi.org\/10.17998\/JLC.2023.11.21.","journal-title":"J Liver Cancer"},{"key":"2099_CR176","doi-asserted-by":"publisher","unstructured":"Tian JC et al. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis, Clin. Exp. Med., vol. 23, no. 6, pp. 2115\u20132129, 2023, https:\/\/doi.org\/10.1007\/S10238-022-00938-6","DOI":"10.1007\/S10238-022-00938-6"},{"issue":"4","key":"2099_CR177","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030.","journal-title":"J Hepatol"},{"key":"2099_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-025-14540-Y","author":"X Li","year":"2025","unstructured":"Li X, Sun H, Wang J, Chen L. Predicting the occurrence of liver injury induced by immune checkpoint inhibitors in hepatocellular carcinoma patients: a retrospective analysis. BMC Cancer. 2025. https:\/\/doi.org\/10.1186\/S12885-025-14540-Y.","journal-title":"BMC Cancer"},{"key":"2099_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS16112042","author":"M Ruli","year":"2024","unstructured":"Ruli M, Pollack ED, Lodh A, Evers CD, Price CA, Shoreibah M. Immune checkpoint inhibitors in hepatocellular carcinoma and their hepatic-related side effects: a review. Cancers. 2024. https:\/\/doi.org\/10.3390\/CANCERS16112042.","journal-title":"Cancers"},{"key":"2099_CR180","doi-asserted-by":"publisher","DOI":"10.1186\/S40249-023-01128-6","author":"Z Xia","year":"2023","unstructured":"Xia Z, et al. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Infect Dis Poverty. 2023. https:\/\/doi.org\/10.1186\/S40249-023-01128-6.","journal-title":"Infect Dis Poverty"},{"key":"2099_CR181","doi-asserted-by":"publisher","unstructured":"Li X, Sun H, Wang J, Chen L. Predicting the occurrence of liver injury induced by immune checkpointinhibitors in hepatocellular carcinoma patients: a retrospective analysis. BMC Cancer. Dec. 2025;25(1). https:\/\/doi.org\/10.1186\/S12885-025-14540-Y","DOI":"10.1186\/S12885-025-14540-Y"},{"key":"2099_CR182","doi-asserted-by":"publisher","unstructured":"Ruli TM, Pollack ED, Lodh A, Evers CD, Price CA, Shoreibah M. Immune Checkpoint Inhibitors inHepatocellular Carcinoma and Their Hepatic-Related Side Eff ects: A Review. Cancers (Basel). Jun.2024;16(11). https:\/\/doi.org\/10.3390\/cancers16112042","DOI":"10.3390\/cancers16112042"},{"key":"2099_CR183","doi-asserted-by":"publisher","unstructured":"Xia Z, et al. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematicreview and meta-analysis. Infect Dis Poverty. Dec. 2023;12(1). https:\/\/doi.org\/10.1186\/s40249-023-01128-6","DOI":"10.1186\/s40249-023-01128-6"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02099-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:02:38Z","timestamp":1773248558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02099-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":183,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02099-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In this manuscript, ChatGPT and Grammarly were used for paraphrasing and grammatical corrections.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI tools"}}],"article-number":"181"}}